Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Mutations in calreticulin (CALR) have been reported to be key markers in the molecular diagnosis of myeloid proliferative neoplasms. In most previous reports, CALR mutations were analyzed by using Sanger sequencing. Here, we report a new, rapid, and convenient system for screening CALR mutations without sequencing. Methods: Eighty-three bone marrow samples were obtained from 81 patients with thrombocytosis. PCR primers were designed to detect wild-type CALR (product: 357 bp) and CALR with type 1 (product: 302 bp) and type 2 mutations (product: 272 bp) in one reaction. The results were confirmed by Sanger sequencing and compared with results from fragment analysis. Results: The minimum detection limit of the screening PCR was 10 ng for type 1, 1 ng for type 2, and 0.1 ng for cases with both mutations. CALR type 1 and type 2 mutants were detected with screening PCR with a maximal analytical sensitivity of 3.2% and <0.8%, respectively. The screening PCR detected 94.1% (16/17) of mutation cases and showed concordant results with sequencing in the cases of type 1 and type 2 mutations. Sanger sequencing identified one novel mutation (c.1123_1132delinsTGC). Compared with sequencing, the screening PCR showed 94.1% sensitivity, 100.0% specificity, 100.0% positive predictive value, and 98.5% negative predictive value. Compared with fragment analysis, the screening PCR presented 88.9% sensitivity and 100.0% specificity. Conclusions: This screening PCR is a rapid, sensitive, and cost-effective method for the detection of major CALR mutations.
Abstract
Background: Mutations in calreticulin (CALR) have been reported to be key markers in the molecular diagnosis of myeloid proliferative neoplasms. In most previous reports, CALR mutations were analyzed by using Sanger sequencing. Here, we report a new, rapid, and convenient system for screening CALR mutations without sequencing. Methods: Eighty-three bone marrow samples were obtained from 81 patients with thrombocytosis. PCR primers were designed to detect wild-type CALR (product: 357 bp) and CALR with type 1 (product: 302 bp) and type 2 mutations (product: 272 bp) in one reaction. The results were confirmed by Sanger sequencing and compared with results from fragment analysis. Results: The minimum detection limit of the screening PCR was 10 ng for type 1, 1 ng for type 2, and 0.1 ng for cases with both mutations. CALR type 1 and type 2 mutants were detected with screening PCR with a maximal analytical sensitivity of 3.2% and <0.8%, respectively. The screening PCR detected 94.1% (16/17) of mutation cases and showed concordant results with sequencing in the cases of type 1 and type 2 mutations. Sanger sequencing identified one novel mutation (c.1123_1132delinsTGC). Compared with sequencing, the screening PCR showed 94.1% sensitivity, 100.0% specificity, 100.0% positive predictive value, and 98.5% negative predictive value. Compared with fragment analysis, the screening PCR presented 88.9% sensitivity and 100.0% specificity. Conclusions: This screening PCR is a rapid, sensitive, and cost-effective method for the detection of major CALR mutations.
참고문헌 (21)
- Campbell PJ, "The myeloproliferative disorders", N Engl J Med, 355, pp.2452~2466 (2006)
- Guglielmelli P, "CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum", Am J Hematol, 89, pp.453~456 (2014)
- Nangalia J, "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2", N Engl J Med, 369, pp.2391~2405 (2013)
- Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)
- Cabagnols X, "Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution", Leukemia, 29, pp.249~252 (2015)
- Rotunno G, "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia", Blood, 123, pp.1552~1555 (2014)
- Rumi E, "JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes", Blood, 123, pp.1544~1551 (2014)
- Landis JR, "The measurement of observer agreement for categorical data", Biometrics, 33, pp.159~174 (1977)
- Tefferi A, "Myeloproliferative Neoplasms: A Contemporary Review", JAMA Oncol, 1, pp.97~105 (2015)
- Qiao C, "Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients", Haematologica, 99, pp.e182~e184 (2014)
- Kim SY, "CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable", Am J Clin Pathol, 143, pp.635~644 (2015)
- 하정숙, "Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms", Annals of Laboratory Medicine, 35(1), pp.22~27 (2015), 대한진단검사의학회
- Jones AV, "Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms", Leuk Res, 39, pp.82~87 (2015)
- Chi J, "Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis", Leukemia, 28, pp.1152~1154 (2014)
- Lim KH, "Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis", Blood Cancer J, 5, pp.e295~ (2015)
- Bilbao-Sieyro C, "High resolution melting analysis: a rapid and accurate method to detect CALR mutations", PLoS One, 9, pp.e103511~ (2014)
- Lim KH, "Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis", Clin Chim Acta, 440, pp.133~139 (2015)
- Tefferi A, "Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients", Am J Hematol, 89, pp.E121~E124 (2014)
- Tefferi A, "An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms", Leukemia, 28, pp.1407~1413 (2014)
- Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons", Leukemia, 28, pp.1472~1477 (2014)
- Chen CC, "Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia", Ann Hematol, 93, pp.2029~2036 (2014)